Eras­ca touts ear­ly col­orec­tal can­cer da­ta, trims a slate of tri­als and pre­clin­i­cal pro­grams to re­fine fo­cus

Eras­ca be­lieves it’s se­cured the ear­ly clin­i­cal da­ta to show one of its tar­get­ed ther­a­pies holds promise as a “back­bone” for drug com­bi­na­tions, par­tic­u­lar­ly for col­orec­tal can­cer. But to get there, the biotech is chop­ping a string of com­bo tri­als and oth­er dis­cov­ery-stage pro­grams to nar­row its fo­cus.

Gone are three tri­als pair­ing ERAS-007 with dif­fer­ent drugs (two ap­proved, one ex­per­i­men­tal from Eras­ca’s own pipeline) in var­i­ous can­cer types; a tri­al for a KRAS G12C in­hibitor “due to in­creas­ing­ly com­pet­i­tive land­scape for small- and mid-cap bio­phar­ma com­pa­nies”; and three pre­clin­i­cal can­di­dates hit­ting SOS1, MYC and RAS, re­spec­tive­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER